Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 14/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 12/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | VEGFA | P15692 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2885764 | 0.97 | PDE4A (0.44) | PDE4APDE4BPDE4DPDE4CPOLB | |
| SCHEMBL2887418 | 0.93 | PDE4A (0.44) | PDE4APDE4BPDE4DPDE4CPOLB | |
| SCHEMBL12486463 | 0.93 | PDE4A (0.40) | PDE4APDE4BPDE4DPDE4CPOLB | |
| SCHEMBL8492806 | 0.92 | PDE4A (0.43) | PDE4APDE4BPDE4DPDE4CPOLB | |
| SCHEMBL2887724 | 0.89 | CSNK2A1 (0.37) | PDE4APDE4BPDE4DPDE4CCYP3A4 | |
| SCHEMBL12486421 | 0.86 | PDE4A (0.36) | PDE4APDE4BPDE4DPDE4CPOLB | |
| SCHEMBL17710554 | 0.85 | CSNK2A1 (0.33) | PDE4A | |
| SCHEMBL28757119 | 0.80 | PDE4D (0.44) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL8594006 | 0.80 | PDE4D (0.48) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL2483005 | 0.79 | HTR1A (0.43) | PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 303 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190070149-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-03-07 | — | — | US | claimed |
| US-9328107-B2 | Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2016-05-03 | — | — | US | claimed |
| EP-2146968-B1 | UREA DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2015-09-23 | — | — | EP | claimed |
| EP-2018371-B1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2015-03-04 | — | — | EP | claimed |
| US-20140235622-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | claimed |
| US-8809010-B2 | Method for prophylactic treatment of alzheimer's disease using inhibitors of glutaminyl cyclase and glutamate cyclases | PROBIODRUG AG (DE) | 2014-08-19 | — | — | US | claimed |
| US-8664258-B2 | Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | claimed |
| US-8399466-B2 | Composition for regenerative treatment of cartilage disease | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-03-19 | — | — | US | claimed |
| US-8338120-B2 | Anticancer agents; therapy for infections; administering glutaminyl cyclase inhibitor such as 1-(3-(1H-imidazole-1-yl)propyl)-3-(3,4-dimethoxy-phenyl)thiourea hydrochloride; Alzheimer's disease; Down syndrome; controlling fertility; schizophrenia; skin disorders; dementia | PROBIODRUG AG (DE) | 2012-12-25 | — | — | US | claimed |
| US-20120270861-A1 | Primary Amines And Derivatives Thereof As Modulators Of The 5-HT2A Serotonin Receptor Useful For The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. | 2012-10-25 | — | — | US | claimed |
| WO-1998024763-A2 | IMMUNOTHERAPEUTIC IMIDES/AMIDES AS PDE IV AND TNF INHIBITORS | CELGENE CORPORATION (US) | 1998-06-11 | — | — | WO | claimed |
| US-5703098-A | INHIBITORS OF CYTOKINES INCLUDING TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-12-30 | — | — | US | claimed |
| EP-0785927-A4 | NOVEL BENZOXAZOLES | EURO CELTIQUE SA (LU) | 1997-12-29 | — | — | EP | claimed |
| JP-H09510691-A | — | — | 1997-10-28 | — | — | JP | claimed |
| US-5665737-A | PHOSPHODIESTERASE INHIBITORS | EURO-CELTIQUE, S.A. (LU) | 1997-09-09 | — | — | US | claimed |
| EP-0785927-A1 | NOVEL BENZOXAZOLES | Euroceltique S.A. (LU) | 1997-07-30 | — | — | EP | claimed |
| US-5608070-A | ENZYME INHIBITOR; ANTIINFLAMMATORY, BRONCHODILATOR AGENTS | CELLTECH THERAPEUTICS LIMITED (GB) | 1997-03-04 | — | — | US | claimed |
| EP-0736010-A1 | AN ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF CHIRAL TRIARYL DERIVATIVES AND CHIRAL INTERMEDIATES FOR USE THEREIN | CELLTECH THERAPEUTICS LIMITED (GB) | 1996-10-09 | — | — | EP | claimed |
| WO-1996011917-A1 | NOVEL BENZOXAZOLES | EURO-CELTIQUE, S.A. (LU) | 1996-04-25 | — | — | WO | claimed |
| WO-1995017386-A1 | AN ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF CHIRAL TRIARYL DERIVATIVES AND CHIRAL INTERMEDIATES FOR USE THEREIN | CELLTECH THERAPEUTICS LIMITED (GB) | 1995-06-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235622-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR1A | PDE4A 546/4885PDE4B 721/4885PDE4D 654/4885 |
| US-20190070149-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR1A | PDE4A 546/4885PDE4B 721/4885PDE4D 654/4885 |
| US-20120270861-A1 | Primary Amines And Derivatives Thereof As Modulators Of The 5-HT2A Serotonin Receptor Useful For The Treatment Of Disorders Related Thereto | HTR5A, HTR2A, HTR1A | PDE4A 546/4885PDE4B 721/4885PDE4D 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.